Flerie AB (FRA:1NP1) ROCE %: -6.40% (As of Mar. 2026)


FRA:1NP1 Flerie AB FRA:1NP1
27 GF Score
Price €1.71
! 1 Warning Sign
View Full Analysis

What is Flerie AB ROCE %?

Flerie AB FRA:1NP1 27 ROCE % is -6.40% as of Mar. 2026. GuruFocus rates FRA:1NP1 with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Flerie AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -6.40%.

Flerie AB  (FRA:1NP1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Flerie AB ROCE % Related Terms

Flerie AB ROCE % Historical Data

* Premium members only.

The historical data trend for Flerie AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Flerie AB ROCE % Chart

Flerie AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -42.35 -25.00 -27.81 -5.75 -20.57

Flerie AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.02 -0.35 -13.38 -58.44 -6.40
FRA:1NP1
27GF Score
Flerie AB FRA:1NP1
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Flerie AB ROCE % Calculation

Flerie AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-69.572/( ( (367.16 - 1.608) + (312.176 - 1.277) )/ 2 )
=-69.572/( (365.552+310.899)/ 2 )
=-69.572/338.2255
=-20.57 %

Flerie AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-20.872/( ( (312.176 - 1.277) + (342.019 - 0.724) )/ 2 )
=-20.872/( ( 310.899 + 341.295 )/ 2 )
=-20.872/326.097
=-6.40 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -6.40% mean?
Flerie AB (FRA:1NP1) has a ROCE % of -6.40% as of Mar. 2026.
Is Flerie AB's ROCE % too high?
Flerie AB's current ROCE % is -6.40%. Overall, Flerie AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Flerie AB's ROCE % compare to VRTX and REGN?
Flerie AB's ROCE % of -6.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Flerie AB's current ROCE % is -6.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Flerie AB stock overvalued right now?
Flerie AB (FRA:1NP1) has a current ROCE % of -6.40%. The current ROCE % is -6.40%. Flerie AB's overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Flerie AB (FRA:1NP1), the current ROCE % is -6.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Flerie AB Business Description

Other Exchanges FLERIE:Sweden1NP1:Germany
Address Skeppsbron 16, Stockholm, SWE, 111 30
Flerie AB is a pharmaceutical company focusing on immunological diseases with great medical needs for new treatment options. The portfolio of the company includes Immuno-Oncology, metabolic diseases, and biologics development and manufacturing organizations. It operates in two segments The Product Development segment, and The Commercial Growth segment. The Product Development segment consists of early and mid-stage biotech and pharma companies advancing their products and technologies toward clinical proofof-concept and marketing approvals. The Commercial Growth segment consists of companies already selling products or services, showcasing their ability to generate increasing revenues ahead of reaching sustainable profitability.
27GF Score

Get the complete analysis for FRA:1NP1

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.71
Price